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Semaphorin 5A drives melanoma
progression: role of Bcl-2, miR-204
and c-Myb
Simona D’Aguanno1*†, Elisabetta Valentini1†, Maria Grazia Tupone1, Marianna Desideri1, Marta Di Martile1,
Manuela Spagnuolo2, Simonetta Buglioni3, Cristiana Ercolani3, Italia Falcone4, Marco De Dominici5, Michele Milella4,
Maria Giulia Rizzo2, Bruno Calabretta5, Carlo Cota6, Andrea Anichini7, Daniela Trisciuoglio1,8 and Donatella Del Bufalo1*

Abstract
Background: Melanoma, the most aggressive form of skin cancer, is characterized by high rates of metastasis, drug
resistance and mortality. Here we investigated the role of Semaphorin 5A (Sema5A) on the properties associated with
melanoma progression and the factors involved in Sema5A regulation.
Methods: Western blotting, qRT-PCR, Chromatin immunoprecipitation (ChIP) assay, immunohistochemistry of
melanoma patient specimens and xenograft tissues, in vitro Transwell assay for cell migration and invasion evaluation,
in vitro capillary-like structure formation analysis.
Results: A significant correlation of Sema5A mRNA expression and melanoma progression was observed by analyzing
GEO profile dataset. Endogenous Sema5A protein was detected in 95% of human melanoma cell lines tested, in 70%
of metastatic specimens from patients affected by melanoma, and 16% of in situ melanoma specimens showed a focal
positivity. We demonstrated that Sema5A regulates in vitro cell migration and invasion and the formation of
vasculogenic structures. We also found an increase of Sema5A at both mRNA and protein level after forced expression
of Bcl-2. By use of transcriptional and proteasome inhibitors, we showed that Bcl-2 increases the stability of Sema5A
mRNA and protein. Moreover, by ChIP we demonstrated that Sema5A expression is under the control of the
transcription factor c-Myb and that c-Myb recruitment on Sema5A promoter is increased after Bcl-2 overexpression.
Finally, a concomitant decrease in the expression of Sema5A, Bcl-2 and c-Myb proteins was observed in melanoma
cells after miR-204 overexpression.
Conclusion: Overall our data provide evidences supporting the role of Sema5A in melanoma progression and the
involvement of Bcl-2, miR-204 and c-Myb in regulating its expression.
Keywords: Melanoma, Semaphorin 5A, Bcl-2, c-Myb, miR-204

Introduction
Semaphorins (SEMAs), a large family of phylogenetically
conserved proteins classified into eight classes, are involved
in different physiological and developmental functions, including regulation of the nervous and immune systems and
angiogenesis [1]. In the past years, several studies have
shown that SEMAs and their receptors also regulate
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tumour growth and metastasis [2], but the mechanism of
action in cancer, and particularly in melanoma, is not completely understood. Sema3A, Sema3B and Sema3F have
been long considered inhibitors of tumor growth and
metastasis [3–5], even if it has been reported that Sema3E
inhibits tumor growth but promotes metastasis [6]. On the
contrary, Sema6A positively correlates with melanoma migration [7] and Sema7A is associated with melanoma metastasis [8]. Controversial data exist regarding the role of
Sema5A in cancer [9]. Reduced expression of Sema5A was
observed in clinical samples of high-grade astrocytomas
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compared to normal brain tissue, and Sema5A was found
to inhibit migration and invasion in human glioma cells by
interacting with the plexin-B3 receptor and disrupting Rac1
activity [10]. Downregulation of Sema5A in tumor tissues
was also reported in non-smoking women with non-small
cell lung carcinoma and was associated with poor survival
[11]. On the contrary, Sema5A was reported to promote invasion/metastasis in gastric cancer through activation of
metalloprotease-9 (MMP-9) and urokinase-type plasminogen activator, and to increase pancreatic cancer metastasis
via the Met receptor tyrosine kinase or the MEK/ERK pathway [11–15]. The ability of Sema5A to enhance metastases
formation in some cancer models has been ascribed to its
effect on angiogenesis: in vivo Matrigel plug assays demonstrated that Sema5A promotes angiogenesis and treatment
of endothelial cells with recombinant extracellular domain
of Sema5A enhanced endothelial cells proliferation,
through Akt pathway activation, and increased migration
through Met tyrosine kinase receptor and upregulation of
MMP-9 [14].
In this study, we investigated the role of Sema5A in
melanoma progression, and the molecular mechanism
regulating its expression. We also focused on the functional relation between Sema5A and Bcl-2, an
anti-apoptotic protein associated with melanoma progression, resistance to apoptosis and poor prognosis
[16]. We previously demonstrated that, in addition to its
canonical anti-apoptotic role, Bcl-2 is involved in multiple non-canonical functions, including melanoma metastasis, angiogenesis, and autophagy [17]. In particular,
Bcl-2 overexpression in human melanoma cells increases
in vitro and in vivo tumor progression-associated properties and angiogenesis [17–21] and promotes a cancer
stem cell phenotype [22]. Moreover, treatment of melanoma cells with Bcl-2 antisense oligonucleotides induces
antiangiogenic activity [23] and increases sensitivity to
antineoplastic treatments [24]. We have also shown that
Bcl-2 regulates the activity of transcription factors, such as
microphthalmia-associated transcription factor, a master
regulator of melanocyte and melanoma biology, and consequently its specific target genes, TRPM1, MLANA and
miR-211 [25].
In this paper, we evidence Sema5A expression in
metastatic specimens from melanoma patients, and we
show that Sema5A expression modulates in vitro melanoma cell migration and invasion, activates the Akt/ERK
pathway and is regulated by Bcl-2 and the miR-204/
c-Myb axis.

Methods
Patients and tissue samples

Thirteen cases of metastatic melanoma specimens used to
analyse Sema5A expression were obtained from melanoma
patients surgically treated at the IFO-Regina Elena National
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Cancer Institute. The 13 metastatic specimens were obtained from the biopsies with different localization: 6 inguinal lymph nodes, 2 laterocervical lymph nodes, 1
parathyroid lymph node, 1 subscapularis lymph node, 2
brain and 1 lung metastatic lesions. We also analyzed
Sema5A expression in specimens from in situ melanoma
lesions (early melanoma lesions devoid the basement membrane invasion) from 12 patients collected at the IFO-San
Gallicano Dermatological Institute. Three-micrometer sections of formalin-fixed paraffin-embedded tumor samples
were cut on SuperFrost Plus slides (Menzel-Gläser, Braunschweig, Germany). Immunoreactions were revealed by
Bond Polymer Refine Detection in an automated autostainer (Bond III, Leica Biosystems, Wetzlar, Germany) using
Sema5A polyclonal antibody (#PA5–30884, ThermoFisher,
Waltham, MA, USA). Diaminobenzidine was used as
chromogenic substrate. The immunohistochemistry (IHC)
results for Sema5A were recorded as positive when > 10%
of the neoplastic cells showed distinct immunoreactivity.
Staining was classified in: SCORE 1+ (staining that is faint/
barely detectable), SCORE 2+ (staining that is weak/moderate), SCORE 3+ (staining that is intense/strong). Images
were acquired with original magnification × 400.
Human microarray dataset analysis

Data from the microarray datasets GDS3964 and GDS1375
were downloaded from the Gene Expression Omnibus
(GEO, https://www.ncbi.nlm.nih.gov/geoprofiles) website.
GDS3964 GEO profile dataset was obtained in xenotransplant melanoma metastasis models, comparing genes differentially expressed between tumor samples derived from
a poorly metastatic parental cell lines, and from their
highly metastatic derivatives. GDS1375 GEO profile dataset has been constructed based on the expression profile in
normal skin samples (normal), benign skin nevi (benign
nevi) and primary malignant melanoma (malignant). Statistical analysis was performed applying Mann-Whitney test.
p < 0.05 was considered significant.
Cell lines, transfection and viral infection

M14 and SKMEL24 human melanoma cell lines were purchased from American Type Culture Collection (ATCC,
Manassas, VA). PLF2, SAN, M20, SKMel28, Sbcl1, A375,
JR8, ME1007 human melanoma cell lines were established
at the Regina Elena National Cancer Institute [22, 26, 27].
ME4405, ME4686, ME8959, and ME10538 human melanoma cell lines were established by Dr. Andrea Anichini
(Istituto Nazionale Tumori, Milan, Italy), as previously described [22, 26, 27]. C32 and WM115 human melanoma
cell lines were kindly donated by Dr. Meenhard Herlyn
(Wistar Institute, Philadelphia, USA), and by Dr. Federica
Di Nicolantonio (University of Turin, Turin, Italy), respectively [22, 26, 27]. ME1, ME70 and ME47 were provided by Dr. Andrea Anichini.
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All cell lines were cultured in RPMI medium (Euroclone, Milan, IT) containing 10% inactivated fetal bovine
serum (FBS) (Hyclone, Thermo Scientific, South Logan,
UT), 2 mM L-glutamine (Euroclone), and antibiotics, as
previously described [22, 26, 27]. Cell lines have routinely been tested for mycoplasma contamination.
Stable control (empty) and Bcl-2 (bcl-2) overexpressing clones were generated by M14 and A375SM-SC1 human melanoma cells as previously described [21, 25].
These cells were cultured in complete RPMI medium in
presence of 1 mg/ml puromicine (Sigma–Aldrich, St
Louis, MO).
1.5 × 105 M14 cells were seeded and 24 h later transfected with a 50 nM pooled oligonucleotide mix against
Sema5A (si-Sema5A) or scramble target (si-Ctrl) sequences
(DharmaconRNA Technologies, siGENOMES MARTpool,
Lafayette, CO, USA) using jetPRIME (Polyplus Transfection, Sébastien Brant Illkirch, FRANCE) following the
manufacturer’s protocol. 48 h after transfection, Sema5A
protein expression was assessed by Western blot analysis.
For Sema5A protein expression, 1.5 × 105 M14 cells were
seeded and after 24 h were transfected with an empty vector (control plasmid, Ctrl) or Sema5A-Fc-His plasmid
(2 μg), expressing the extracellular domain of the murine
Sema5A protein (ECD-Sema5A), C-terminally fused to the
Fc region of human IgG1 in addition to a 6X Histidine tag
(a gift from Dr. Woj Wojtowicz Addgene plasmid #72161)
[28] using jetPRIME (Polyplus Transfection) following the
manufacturer’s protocol. Sema5A protein expression was
assessed after 48 h of transfection by Western blot analysis.
Stable Sema5A clones were obtained by transfecting M14
parental cell line with plasmid expressing the full length
human Sema5A protein (Sema5A Protein Vector, pPMC-HA, #PV057575, www.abmgood.com, Richmond, BC,
Canada). The corresponding empty vector (#PV001) was
used as control plasmid (empty). After transfection by JetPRime reagent (Polyplus transfection) according to the
manufacturer’s protocol, M14 cells were cultured in the
presence of 1200 μg/ml geneticin. A375 and BV173 cells
were transduced with lentiviral vector for inducible c-Myb
silencing [29], cultured in DMEM medium (Euroclone,)
containing 10% inactivated fetal bovine serum (FBS)
(Hyclone), 2 mM L-glutamine (Euroclone), and antibiotics,
and exposed or not to doxycycline (doxy, 1 μg/ml for 72 h,
RPI corp. Mount Prospect, Illinois, USA). M14 cells were
transfected with mimic miR-204 (mirVana miRNA Mimic,
hsa-miR-204-5p, ThermoFisher) or mimic miRNA negative
control (mirVana miRNA Mimic, Negative Control #1,
ThermoFisher) at final concentration of 10 nM. INTERFERin transfection reagent (Polyplus Transfection) was
used according to the manufacturer’s instructions. Mature miRNA was assayed 72 h after transfection by
stem-loop PCR [30] and samples were normalized using
RNU19 as endogenous control. RNA quantification of
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mature miR-204 expression was performed by quantitative
RT-PCR using TaqMan, Universal PCR Master Mix No
AmpErase UNG (Applied Biosystems by Thermo Scientific).
Western blotting analysis

Antibodies directed to Sema5A (#AP12324PU-N, OriGene,
Rockville, Maryland, US), AKT (#9272S Cell Signaling,
Danvers, MA, USA), phosphorylated AKT (#9271S, Cell
Signaling), p44/42 (ERK1/2, #9102, Cell Signaling), phosphorylated p44/42 (ERK1/2, #9106 L, Cell Signaling),
c-Myb (#AB45150, Abcam, Cambridge, MA, USA) were
used. β-actin (#A1978, Sigma-Aldrich) and HSP70/72
(#HSP01, Calbiochem, San Diego, CA, USA) were used to
check equivalent transfer and loading. Antibody binding
was visualized by enhanced chemiluminescence method
(Pierce ECL Plus Western Blotting Substrate, Thermo Scientific) according to manufacturer’s specification. The
densitometric evaluation was performed using Image J
software and normalized with relative controls.
Cell migration and invasion assays

M14 cells, after 48 of transfection, were subjected to cell
migration and invasion assays for 8 h as described [22].
Cell migration was also evaluated after pharmacological
inhibition of MEK. 48 h after transfection, M14 cells
were left untreated or treated with 10 nM Trametinib
(GSK1120212, Selleckcem, Munich, Germany) for 6 h,
then trypsinized and subjected to cell migration assays
for 18 h.
Vasculogenic mimicry (VM)

In vitro vasculogenic mimicry assay was performed seeding 1 × 105 melanoma cells in serum-free medium onto
the gelled basement matrix extracts, as described [22].
After 6 h, VM formation was photographed using light
microscopy and quantified by counting the number of
capillary-like structures in 10 set of images for each clone.
Each clone was analyzed in duplicate in three different experiments. Statistical analysis was performed applying Student’s t-test. p < 0.05 was considered significant.
In vivo experiments

Control (empty) and Bcl-2 (bcl-2) overexpressing cells in
exponential growth phase were harvested from the culture, washed, and resuspended in PBS and 5 × 106 viable
cells/mice were intramuscular injected into female CD-1
nude (nu/nu) mice (Charles River Laboratories, Calco,
Italy) [31]. Mice were sacrificed 15 days after tumor injection and Sema5A expression in tumor sections was
evaluated using Sema5A polyclonal antibody following
the procedure described for the analysis of patient specimens. Representative images of immunohistochemical
expression of Sema5A in empty and bcl-2 overexpressing xenografts were acquired by microscopy by original
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magnification × 400. All procedures involving animals
and their care were authorized and certified by D.lgs 26/
2014 (816/2015-PR of 11/08/2015) of the Italian Minister of Health.
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minimum of three replicates, unless specified. Results
were evaluated by Student’s t-test, with p < 0.05 considered significant.

Results
Quantitative real-time polymerase chain reaction (qRTPCR) analysis

Sema5A affects in vitro melanoma cell invasion,
migration and vasculogenic mimicry (VM)

Total RNA was extracted from cultured cells using a
Qiagen RNeasy Mini kit (Qiagen, Redwood City, CA,
USA) according to the manifacturer’s instructions. Reverse transcription was performed using RevertAid Reverse Transcriptase (Thermo Scientific). qRT-PCR was
performed with a Gene-Amp 7900 sequence detection
system (Applied Biosystems, Foster City, CA, USA),
using the SYBR green dye detection method. The mRNA
levels were normalized using β-actin (ACTB) transcript.
Relative mRNA levels were measured using the 2-Δ cycle
threshold (2-ΔCT) method. Primers used to analyze each
gene were: Sema5A: 5’-ACTGTTCTAGCGACGGCACC-3′
(forward), 5’-CCCCAGAAAGCCCATCTGT-3′(reverse), cMyb: 5’-AAGTCTGGAAAGCGTCACTTG-3′ (forward), 5’
-ACATCTGTTCGATTCGGGAGATA-3′ (reverse), β-actin:
5’-ATTGCCGACAGGATGCAGAA-3′ (forward), 5’-GCT
GATCCACATCTGCTGGAA-3′ (reverse). Student’s t-test
was used and results were considered significant if p < 0.05.

By interrogating Protein Atlas database (https://
www.proteinatlas.org) we observed that Sema5A protein
and mRNA are expressed in all tested cancer types, including melanoma. Since little is known regarding the
role of Sema5A in melanoma, except for its detection in
membrane preparations [9], we evaluated Sema5A expression in melanoma, by analysing the gene expression profiles. As shown in Fig. 1a, a significant up-regulation of
Sema5A expression was observed in tumors derived from
highly metastatic human cells, and increased Sema5A levels
were observed in malignant samples compared to benign
nevi. Moreover, as shown in Fig. 1b, Sema5A protein is
expressed, although at different levels, in 18 out 19 (95%)
human melanoma cell lines analysed. We also evaluated
the expression of Sema5A protein by immunohistochemistry (IHC) in metastatic lesions from 13 patients with melanoma, finding 70% of positive specimens (Fig. 1c-e). In
particular, 2 cases showed SCORE 1+, 4 cases showed a
moderately staining (SCORE 2+), and 3 cases were highly
positive (SCORE 3+). On the other hand, immunoreactivity
was not observed in 10/12 (Fig. 1f) human in situ melanoma lesions, while two cases showed a focal positivity
(SCORE 1+) in a < 1% of melanoma cells (Fig. 1g).
These results and the lack of published data on the
relevance of Sema5A on melanoma prompted us to
evaluate the role of Sema5A in melanoma aggressiveness. To this purpose, we performed in vitro transwell
migration assays of Sema5A-silenced M14 cells. As
depicted in Fig. 2, Sema5A downregulation (Fig. 2a) induced a decrease in migration (Fig. 2b, Additional file 2:
Figure S1) and invasion (Fig. 2c, Additional file 2: Figure S1)
of about 50%, when compared to cells transfected with
control siRNA. We confirmed the role of Sema5A in
regulating cell migration and invasion in M14 cells
transiently transfected with a plasmid expressing the
extracellular domain of Sema5A (ECD-Sema5A). As
shown in Fig. 2, the number of migrating (Fig. 2d,
Additional file 2: Figure S1) and invading (Fig. 2e,
Additional file 2: Figure S1) cells was significantly
higher in Sema5A-overexpressing cells, compared to control ones. These results indicate that Sema5A regulates
aggressiveness-associated properties of melanoma cells.
To identify a signalling network mediating Sema5A migration and invasion, we examined the effect of Sema5A
overexpression on phosphorylation of Akt and ERK1/2
(p42/44 MAPK) [34]. Fig. 2f shows that overexpressing
Sema5A increased levels of Akt and p42/44 ERK1/2

mRNA decay measurement

Actinomycin D (10 μg/ml, Sigma-Aldrich) was added to
control (empty) and Bcl-2 (bcl-2) overexpressing cells to
inhibit mRNA transcription and to assess the stability of
the Sema5A mRNA. Total RNA was extracted at 0, 90,
180, and 360 min after treatment. The relative amount
of specific mRNA remaining in each sample at specified
time points can be correlated with mRNA degradation
[32]. The endogenous Sema5A mRNA levels were analysed by qRT-PCR. Since the mRNA level for ACTB did
not change after Actinomycin D treatment, the ACTB
gene was used as a reference gene, and the ratio of
Sema5A and ACTB in each sample was calculated.
Chromatin Immunoprecipitation (ChIP) Assay

Cross-linked chromatin was immunoprecipitated with
anti-c-Myb (ChIP grade, #AB45150, Abcam) or anti-acetyl
histone H3 PAN (#06–599, Millipore, Darmstadt,
Germany) antibodies as described [33]. The genomic regions in the Sema5A and cyclin B1 (CCNB1) promoters
were amplified using specific primers (Additional file 1:
Table S1). Quantization of immunoprecipitated DNA was
performed in triplicate using the SYBR green dye detection method.
Statistical analysis

Values were presented as mean ± standard error of the
mean (SEM) or mean ± standard deviation (SD), with a
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(See figure on previous page.)
Fig. 1 Evaluation of Sema5A expression in melanoma. a Box and whisker plots showing data from the microarray datasets GDS3964 and
GDS1375 downloaded from the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geoprofiles) website (see Methods for details).
Values of Sema5A gene expression levels are reported as counts. Statistical analysis was performed applying Mann-Whitney test. b Western
blotting analysis of Sema5A protein expression in melanoma parental cell lines. Reported image is representative of two independent
experiments with similar results. β-actin expression was evaluated as control of equivalent transfer and loading. c-g IHC analysis of Sema5A
expression in human melanoma specimens. c-e Three representative samples showing different levels of Sema5A selected from metastatic
specimens obtained from melanoma patients: c SCORE 1+ (staining that is faint/barely detectable), d SCORE 2+ (staining that is weak/moderate),
e SCORE 3+ (staining that is intense/strong). Scale bar 20 μm. f, g Representative images from in situ melanoma specimens showing no
immunoreactivity f or focal positivity g for Sema5A expression. Arrow indicates positive cell. Scale bar 30 μm

phosphorylation. Treatment of ECD-Sema5A-transfected
melanoma cells with Trametinib, a specific MEK inhibitor
used for melanoma therapy [35, 36], significantly reduced
the ability of Sema5A- overexpressing cells to migrate
(Fig. 2g, Additional file 2: Figure S2), thus indicating
that Sema5A-dependent cellular migration is mediated
by activation of MEK pathway.
We further investigated the potential role of Sema5A
on VM, a process that reflects the plasticity of aggressive
melanoma cells by forming de novo vascular networks
and is associated with the malignant phenotype and poor
clinical outcome [37, 38]. To this end, we evaluated the
formation of vascular channels after seeding melanoma
cells (Additional file 2: Figure S3) onto the gelled basement matrix extracts. As shown in Fig. 2h and Fig. 2i,
two Sema5A-overexpressing clones showed enhanced
VM, evaluated on the number of capillary-like structures, when compared to the control clone. Enhanced
VM was associated to increased secretion of VEGF protein, determined by ELISA, in two Sema5A transfectants, with a fold induction of 1.7 ± 0.2 and 1.8 ± 0.6
compared to controls.
Bcl-2 modulates Sema5A expression in melanoma models

By using M14 and A375SM-SC1 melanoma cell lines
and their derivatives stably overexpressing wild-type
Bcl-2 [25], we evaluated whether Bcl-2, a protein involved in melanoma progression, resistance to apoptosis,
and poor prognosis [16], plays a role in the regulation of
Sema5A expression. As shown in Fig. 3, increased
Sema5A expression at both protein (Fig. 3a) and mRNA
(Fig. 3b) level was found after Bcl-2 overexpression in
both cell lines. By performing immunofluorescence and
co-immunoprecipitation experiments, we excluded the
possibility of cellular co-localization/interaction of Bcl-2
and Sema5A proteins (data not shown).
To investigate whether Bcl-2 has a role in regulating
Sema5A transcription, we evaluated Sema5A transcripts
at different times after treatment with Actinomycin D, a
classical inhibitor of transcription elongation. As shown
in Fig. 3c, exposure to Actinomycin D caused a significant reduction of Sema5A mRNA expression, while no
appreciable decrease of Sema5A transcripts was detected
in the Actinomycin D-treated Bcl-2-overexpressing cells.

These results indicate the involvement of Bcl-2 in
Sema5A mRNA stability.
We also analysed the level of Sema5A protein after
treatment of A375SM-SC1 cells with MG132, a proteasome inhibitor. As shown in Fig. 3d,e, upon treatment
with MG132, control cells showed an about two-fold increase of Sema5A protein level, while in Bcl-2 overexpressing cells the increase of Sema5A protein expression
was more modest, indicating that Bcl-2 forced expression protects Sema5A protein from proteasome degradation. Most remarkably, the increment of Sema5A
expression after Bcl-2 forced overexpression was also
observed in in vivo experiments (Fig. 3f ). Immunohistochemical analysis revealed higher Sema5A positivity in
Bcl-2 overexpressing xenografts [31] compared to control xenografts.
Sema5A is regulated by the miR-204/c-Myb axis

To investigate the molecular mechanism responsible for
Sema5A regulation, we interrogated bioinformatics tools
(ALGGEN–PROMO, Gene Cards [Genomics for SEMA5A
Gene, Transcription factor binding sites by QIAGEN in the
SEMA5A gene promoter] and Lasagna) for prediction of
putative transcription factor binding sequences in the
Sema5A promoter. Superimposing results were obtained by
three different sources, identifying a c-Myb binding site in
the Sema5A promoter. As shown in Additional file 2:
Figure S4, c-Myb protein is expressed in most of the analysed melanoma cell lines, and more importantly, Bcl-2
overexpressing A375SM-SC1 cells exhibit a higher level of
c-Myb protein (Fig. 4a) and mRNA (Fig. 4b) when compared to control cells. Then, we investigated whether
c-Myb binds directly to the Sema5A promoter. As control,
we also amplified the promoter region containing the
c-Myb binding site of cyclin B1 (CCNB1), a c-Myb target
gene [39]. The results of ChIP analysis confirmed c-Myb recruitment to the Sema5A promoter (Fig. 4c). Interestingly,
in agreement with western blots showing a higher level of
c-Myb protein in Bcl-2 overexpressing cells (Fig. 4a), ChIP
analysis showed that more c-Myb was bound to both
Sema5A and CCNB1 promoters after Bcl-2 overexpression
(Fig. 4c). To confirm the role of c-Myb in the transcription
of Sema5A, we also evaluated the enrichment of acetylated
histone H3 (H3acPAN), a marker of transcriptionally active
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Fig. 2 Sema5A affects in vitro melanoma cell invasion, migration and vasculogenic mimicry. a Western blotting analysis of Sema5A expression in
M14 cells after 48 h transfection with pooled oligonucleotide mix against Sema5A (si-Sema5A) or scramble target (si-Ctrl) sequences. β-actin was
evaluated as control of equivalent transfer and loading. Reported images are representative of three independent experiments with similar results.
b In vitro cell migration and c invasion assay performed in M14 cells transfected with si-Ctrl or si-Sema5A. Values are presented as percentage of
migrated/invaded cells in si-Sema5A versus control cells. d In vitro cell migration and (e) invasion assay performed in M14 cells transfected with
empty vector (Ctrl) or vector expressing the Sema5A protein (ECD-Sema5A). Values are expressed as a percentage of migrated/invaded cells in
ECD-Sema5A versus control cells. b-e Data were expressed as average ± standard deviation. *p-values < 0.05. f Western blotting analysis of
Sema5A, total and phosphorylated AKT, total and phosphorylated p44/42 protein expression in M14 cells transfected with Ctrl and ECD-Sema5A
vectors. Representative images of three independent experiments are reported. β-actin or HSP70/72 expression was evaluated as control of
equivalent transfer and loading. g In vitro cell migration performed in M14 cells transfected with Ctrl or ECD-Sema5A, untreated or treated with
10 nM Trametinib. Values are expressed as a percentage of migrated cells in ECD-Sema5A versus control cells. Data are expressed as average ±
standard deviation. *p-values < 0.05. h Representative images and i quantification of capillary-like structure formation in M14 melanoma clones
overexpressing Sema5A protein (FL-Sema5A/1 and FL-Sema5A/6) and corresponding control clone (empty). Data were expressed as average ±
standard deviation. ***p-values < 0.001. Scale bar, 300 μm

chromatin, at the c-Myb binding site of the Sema5A
promoter. ChIP analysis showed an enrichment of
H3acPAN at the c-Myb binding site of the Sema5A
promoter that was increased in Bcl-2 overexpressing
cells, compared to controls (Fig. 4d). To further investigate the role of c-Myb in the regulation of Sema5A, we
used A375 melanoma cells transduced with a lentiviral
vector for doxycycline-inducible c-Myb silencing [29].
As shown in Fig. 4e, expression of Sema5A protein was
downregulated after c-Myb silencing in A375 cells. Decreased expression of Sema5A was also observed in the
BV173 human chronic myeloid leukemia (CML)-lymphoid blast crisis cells transduced with the same c-Myb
lentiviral vector (Fig. 4e), confirming that c-Myb regulates the expression of Sema5A.
A recent paper reported that miR-204, a microRNA involved in melanoma progression and response to chemotherapy [40, 41], regulates c-Myb expression in metastatic
prostate cancer [42]. Thus, to investigate whether miR-204
regulates Sema5A expression through c-Myb, M14 cells
were transiently transfected with mimic miR-204 (Fig. 5a)
and the expression of both c-Myb and Sema5A was evaluated. Like in prostate cancer [42], c-Myb protein expression decreased after miR-204 overexpression, compared to
control cells (Fig. 5b). Interestingly, a concomitant reduction of Sema5A protein expression was also observed in
miR-204-transfected cells compared to the control counterpart (Fig. 5b), supporting the hypothesis that miR-204
plays an important role in regulating Sema5A expression.
Overexpression of miR-204 also led to a decrease in Bcl-2
protein levels, in accordance with published data in gastric
cancer [43].
We previously demonstrated that overexpression of
Bcl-2 downregulates both miR-211 and miR-204 [25]. As
displayed in Fig. 5c, M14 Bcl-2 overexpressing cells
showed lower level of miR-204 respect to control cells
and overexpression of synthetic miR-204 in both M14
and A375SM-SC-1 Bcl-2 transfectant is able to lower
the level of both Sema5A and c-Myb proteins (Fig. 5d).

These results indicate that the increased level of Sema5A
and c-Myb proteins observed in Bcl-2 overexpressing
clones can be due to the reduced level of miR-204 in
these cells.

Discussion
The aim of this study was to investigate the role of
Sema5A [1, 44], in melanoma progression and to dissect
the molecular mechanisms regulating its expression.
We focused our study on the poorly investigated
Sema5A because, to the best of our knowledge, no data
have been published yet on its expression and/or function in melanoma, but also because of its controversial
role in cancer [9]. Indeed, Sema5A was found to reduce
the motility of glioma cells [10], while having an opposite effect for the invasion of pancreatic, prostatic and
gastric cancer cells [14, 45, 46].
In accordance with previously published studies in
gastric, prostatic and pancreatic cancer, we show here
that overexpression of ECD-Sema5A increased in vitro
cell migration and invasion properties of melanoma
cells, with a concomitant activation of the Akt/ERK
pathways. By treating ECD-Sema5A-overexpressing cells
with Trametinib, we demonstrated that Sema5A regulates cell migration through MEK/ERK activation. Moreover, Sema5A silencing confirmed the role of Sema5A in
melanoma cell migration and invasion. The relevance of
Sema5A in melanoma pathobiology is further supported
by both public database of microarray profiling, showing
higher level of Sema5A transcript in more aggressive
forms of melanoma, and our findings that Sema5A protein is expressed in a panel of human melanoma cell
lines and in metastatic melanoma specimens. On the
contrary, “in situ” melanoma specimens showed only
focal positivity in few cases. These results and data
showing that Sema5A protein increases VM support the
hypothesis that Sema5A expression is associated with
melanoma aggressiveness.
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Fig. 3 Bcl-2 modulates Sema5A expression in melanoma models. a Western blot analysis of Sema5A and Bcl-2 expression in M14 and A375SMSC1 human melanoma control (empty) and Bcl-2 overexpressing (bcl-2) clones. β-actin was evaluated as control of equivalent transfer and
loading. Reported images are representative of three independent experiments with similar results. b Analysis of Sema5A mRNA expression
evaluated by qRT-PCR in the indicated cell lines. mRNA levels were normalized using β-actin. Values are expressed as means of ratio ± SEM where
ratio was calculated considering Bcl-2-overexpressing versus control clones. Experiments were performed at least three times (three technical
replicates). *p-values < 0.05. c Sema5A mRNA amount was evaluated by qRT-PCR in control (empty) and Bcl-2 overexpressing (bcl-2) clones after 0,
90, 180, and 360 min of treatment with Actinomycin D (10 μg/ml). The β-actin (ACTB) gene was used as a reference gene, and the ratio of
Sema5A and ACTB in each sample was calculated. Data are shown as mean ± SD (n = 2). d Western blot analysis of Sema5A in A375SM-SC1
control (empty) and Bcl-2 overexpressing (bcl-2) clones treated or not with 10 μM MG132 (Sigma-Aldrich) for 6 h and e relative densitometric
analysis performed using Image J software. Representative images of two experiments with similar results are reported. β-actin expression was
evaluated to confirm equivalent transfer and loading. f Immunohistochemical analysis of Sema5A expression in M14 control (empty) and Bcl-2
overexpressing (bcl-2) xenografts. Representative images of Sema5A expression in empty (SCORE 1+) and bcl-2 overexpressing (SCORE 3+)
xenografts are reported. Scale bar, 20 μm

As Bcl-2 protein plays a relevant role in melanoma, being associated with melanoma progression, resistance to
apoptosis and poor prognosis [16, 17], we investigated the

effect of Bcl-2 modulation on Sema5A expression. Bcl-2
forced expression in different melanoma models led to increased level of both Sema5A mRNA and protein. By use
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Fig. 4 c-Myb binding to Sema5A promoter. a Western blot analysis of Bcl-2 and c-Myb expression and b qRT-PCR of c-Myb expression in
A375SM-SC1 human melanoma control (empty) and Bcl-2 overexpressing (bcl-2) clones. mRNA levels were normalized using β-actin. Values are
expressed as means of ratio ± SEM where ratio was calculated considering Bcl-2-overexpressing versus control clones. c c-Myb and d H3acPAN
recruitment on Sema5A and Cyclin B1 (CCNB1) promoters by ChIP analysis. Values of each immunoprecipitated sample are expressed as
percentage relative to their respective input and by subtracting the values obtained in the negative controls (no antibody).Values are expressed
as ratio ± SEM where ratio was calculated considering Bcl-2-overexpressing versus control clones. *p-values < 0.05. e Western blot analysis of
Sema5A and c-Myb expression in A375 and BV173 cells transduced with lentiviral vector for inducible c-Myb silencing. a, e, β-actin or HSP70/72
expression was evaluated to confirm equivalent transfer and loading. b, c, d, Experiments were performed at least three times (three
technical replicates). *p-values < 0.05
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Fig. 5 Sema5A is regulated by the miR-204/c-Myb axis. a Quantitative RT-PCR of miR-204 expression in M14 cells 72 h after transfection with
mimic miR-204 or Pre-miRNA Precursor-Negative Control. Values are expressed as means of ratio ± SEM where ratio was calculated considering
mimic miR-204 transfected cells versus control. b Western blot analysis of Sema5A, Bcl-2 and c-Myb expression after mir-204 transfection in M14
cells. c Quantitative RT-PCR of miR-204 expression in M14 human melanoma control (empty) and Bcl-2 overexpressing (bcl-2) clones. Samples
were normalized using RNU19 as endogenous control. Values are expressed as means of ratio ± SEM where ratio was calculated considering Bcl2-overexpressing versus control clones. *p-values < 0.05. d Western blot analysis of Sema5A, Bcl-2 and c-Myb expression after 48 h of miR-204
transfection in Bcl-2 overexpressing (bcl-2) clones from M14 and A375SM-SC1 cells. b, d, β-actin or HSP70/72 expression was evaluated to confirm
equivalent transfer and loading. Representative images of three independent experiments are reported. a, c Experiments were performed at least
three times (three technical replicates). *p-values< 0.05

of transcription and proteasome inhibitors, we found
that Bcl-2 is involved in the regulation of Sema5A
transcript stability and protein degradation, respectively. In particular, Bcl-2 forced expression increased
Sema5A RNA stability and made Sema5A protein less
susceptible to proteasome-dependent degradation.

In agreement with findings in systemic lupus erythematosus patients that show a positive correlation between mRNA expression of ADAM17 and serum level
of Sema5A [47], and with data in HeLa cells showing
the cleavage of Sema5A by ADAM17 [48], we found that
the increased amount of Sema5A levels after forced
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expression of Bcl-2, were paralleled by increased activation of ADAM17 (data not shown), thus suggesting that
Bcl-2 might process Sema5A protein through ADAM17
activation.
We also provided evidence that Sema5A expression is
under the control of the miR-204/c-Myb axis. c-Myb
plays an essential role in regulating cell growth and differentiation of hematopoietic cells [49], promotes
leukemic cell transformation [50], and is also involved in
the development and progression of several solid tumors, including melanoma [51, 52]. More than 80 genes
have been reported to be c-Myb targets, including Bcl-2
[29, 39]. Although at varying levels, c-Myb protein expression was detected in most human melanoma cell
lines analysed. Interestingly, we found a higher level of
c-Myb at both mRNA and protein levels in Bcl-2 overexpressing melanoma cells, and in accordance with this result, the recruitment of the c-Myb protein at the
Sema5A promoter was enhanced by Bcl-2 forced expression. ChIP experiments also showed that, after Bcl-2
forced expression, more c-Myb was bound to the promoter of CCNB1, a well known c-Myb target gene [39].
The observed high acetylation level of the Sema5A promoter region containing the Myb binding site, and the
decrement of Sema5A protein level observed after
c-Myb knockdown in A375 melanoma cells and in
BV173 CML-lymphoid blast crisis cells, confirmed the
c-Myb dependent expression of Sema5A.
A regulatory loop of miR-204-5p and transcription factors, including c-Myb, relevant for malignant lineage development, was recently described [42]. miR-204-5p is
down-regulated and acts as a tumor suppressor in different human tumor types, including melanoma [41, 53–55].
It also contributes to melanoma progression and resistance to BRAF, MEK and ERK inhibitors [41, 56]. On the
basis of these findings, we evaluated the possible involvement of miR-204 in regulating Sema5A expression via
c-Myb. By using a synthetic miR-204 we demonstrated
that melanoma cells overexpressing miR-204 exhibit evident decreased levels of c-Myb together with downregulation of Sema5A, even if with less drastic affect, thus
indication that, although we demonstrated for the first
time the regulation of Sema5A by c-Myb and Bcl-2, other
cellular factors may be involved in the regulation of
Sema5A expression.
We also confirmed the ability of miR-204 to target
Bcl-2, as previously reported in gastric cancer [43],
thus corroborating the correlation between Bcl-2 and
Sema5A expression, initially observed in Bcl-2 overexpressing clones. In accordance with these evidences we observed reduced level of miR-204 in
Bcl-2 overexpressing cells, thus explaining the higher
levels of both Sema5A and c-Myb protein found in
these cells.
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Fig. 6 Schematic representation of the cellular network involved in
the regulation of Sema5A expression. Blue line: evidences previously
reported [29, 39]; violet lines: evidences previously reported [25, 42, 43]
and confirmed in this work; red lines: evidences demonstrated in this
work for the first time

Conclusion
Overall, our findings show that Sema5A promotes the in
vitro migration and invasion of melanoma cells through
Akt/ERK phosphorylation, increasing also VM. In
addition, our data indicate that the miR-204/c-Myb axis
is involved in the regulation of Sema5A expression and
support the existence of a regulatory circuitry involving
miR-204, c-Myb, and Bcl-2 (Fig. 6). Thus, Sema5A could
represent a potential target for the treatment of
melanoma.
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